Artivion's stock plummeted 35.54% during intraday trading on Friday, extending significant losses from the previous session.

The sharp decline follows the company's recent first-quarter earnings report and a downward revision of its full-year 2026 financial outlook. Artivion lowered its revenue guidance to a range of $480 million to $496 million and cut its adjusted EBITDA forecast, prompting multiple Wall Street analysts to slash their price targets on the stock.

Investor sentiment was further impacted by Artivion's announcement of plans to acquire Endospan, developer of the NEXUS Aortic Arch System, for a base purchase price of $175 million in cash. The acquisition and more cautious financial forecast led to a wave of analyst downgrades, with firms including Canaccord Genuity, Stifel, Citizens, and Oppenheimer all reducing their price targets on the healthcare company's shares.